Vericel Corp.
History
| Year | Detail |
|---|---|
| 1989 | Aastrom Biosciences Inc., formerly Vericel Corp., was established to develop patient-specific expanded cellular therapies. |
| 2014 | Vericel Corp. acquired global rights to Carticel, Epicel, and MACI, making it one of the leading providers of cellular therapy worldwide. |
| Aastrom Biosciences Inc. changed its corporate name to Vericel Corp., which the company's shareholders have approved. | |
| 2017 | The U.S. Food and Drug Administration (FDA) has designated the investigation of ixmyelocel‑T to minimize the risk of death and cardiovascular hospitalization in patients with chronic advanced heart failure owing to ischemic dilated cardiomyopathy as a Fast Track Development Program. |
| 2024 | Vericel Corp. announced that the U.S. Food and Drug Administration (FDA) approved a supplemental Biologics License Application (sBLA) that expands the MACI label to include arthroscopic delivery of MACI to repair symptomatic single and multiple full-thickness cartilage defects of the knee up to 4 cm2. |
BCC Research Beacon 